JTT 130
Alternative Names: JTT-130Latest Information Update: 01 May 2012
Price :
$50 *
At a glance
- Originator Japan Tobacco
- Developer Akros Pharma; Japan Tobacco
- Class Antihyperlipidaemics
- Mechanism of Action Microsomal triglyceride transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 26 Apr 2012 Discontinued - Phase-II for Hyperlipidaemia (PO)
- 26 Apr 2012 Discontinued - Phase-II for Hyperlipidaemia in Japan (PO)
- 26 Apr 2012 Discontinued - Phase-II for Type-2 diabetes mellitus in Czech Republic (PO)